ERNA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ERNA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Eterna Therapeutics's enterprise value is $45.20 Mil. Eterna Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $0.07 Mil. Therefore, Eterna Therapeutics's EV-to-Revenue for today is 664.68.
The historical rank and industry rank for Eterna Therapeutics's EV-to-Revenue or its related term are showing as below:
During the past 4 years, the highest EV-to-Revenue of Eterna Therapeutics was 923.74. The lowest was 615.39. And the median was 681.24.
The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.
EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.
As of today (2024-05-13), Eterna Therapeutics's stock price is $2.0201. Eterna Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.01. Therefore, Eterna Therapeutics's PS Ratio for today is 168.34.
The historical data trend for Eterna Therapeutics's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eterna Therapeutics Annual Data | |||||||||
Trend | Dec20 | Dec21 | Dec22 | Dec23 | |||||
EV-to-Revenue | - | - | - | 646.77 |
Eterna Therapeutics Quarterly Data | ||||||||||||||||
Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
EV-to-Revenue | Get a 7-Day Free Trial | - | - | - | 918.49 | 646.77 |
For the Biotechnology subindustry, Eterna Therapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Eterna Therapeutics's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Eterna Therapeutics's EV-to-Revenue falls into.
EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.
Eterna Therapeutics's EV-to-Revenue for today is calculated as:
EV-to-Revenue | = | Enterprise Value (Today) | / | Revenue (TTM) |
= | 45.198 | / | 0.068 | |
= | 664.68 |
Eterna Therapeutics's current Enterprise Value is $45.20 Mil.
Eterna Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.07 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eterna Therapeutics (NAS:ERNA) EV-to-Revenue Explanation
The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.
Eterna Therapeutics's PS Ratiofor today is calculated as:
PS Ratio | = | Share Price (Today) | / | Revenue per Share (TTM) |
= | 2.0201 | / | 0.012 | |
= | 168.34 |
Eterna Therapeutics's share price for today is $2.0201.
Eterna Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.01.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Eterna Therapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Dorothy J Clarke | director | C/O ETERNA THERAPEUTICS INC., 1035 CAMBRIDGE STREET, STE. 18A, CAMBRIDGE MA 02141 |
Charles Cherington | 10 percent owner | ONE BOW STREET, CAMBRIDGE MA 02138 |
Brant Binder | director | C/O TRUST CO OF THE SWEST, 200 PARK AVE SUITE 220, NEW YORK NY 01066 |
Richard W Wagner | director | C/O PRAECIS PHARMACEUTICALS INC, 830 WINTER ST, WALTHAM MA 02451 |
Curtis W Huft | 10 percent owner | 4510 LAMESA HWY, SNYDER TX 79549 |
Freebird Partners Lp | 10 percent owner | 2800 POST OAK BLVD., SUITE 2000, HOUSTON TX 77056 |
Freebird Investments Llc | 10 percent owner | 2800 POST OAK BLVD., SUITE 2000, HOUSTON TX 77056 |
John D Halpern | 10 percent owner | |
Nicholas Jason Singer | director | 1395 BRICKELL AVENUE, SUITE 800, MIAMI FL 33131 |
William A. Wexler | director | 12 GILL STREET, SUITE 4650, WOBURN MA 01801 |
Gregory Fiore | director | 10355 SCIENCE CENTER DRIVE, SUITE 150, SAN DIEGO CA 92121 |
Andrew C. Jackson | officer: Chief Financial Officer | 11988 EL CAMINO REAL STE. 650, SAN DIEGO CA 92130 |
Matthew Angel | officer: Interim President and CEO | 10531 4S COMMONS DRIVE, SUITE 160-550, SAN DIEGO CA 92127 |
Heather B Redman | director | TWO NORTH NINTH STREET, ALLENTOWN PA 18101 |
Erin S. Enright | director | 666 PLAINSBORO ROAD, PLAINSBORO NJ 08536 |
From GuruFocus
By Value_Insider Value_Insider • 10-18-2022
By GuruFocusNews GuruFocusNews • 06-27-2022
By GuruFocusNews GuruFocusNews • 06-10-2022
By GuruFocusNews GuruFocusNews • 06-26-2022
By GuruFocusNews GuruFocusNews • 06-17-2022
By PurpleRose PurpleRose • 07-26-2022
By sperokesalga sperokesalga • 05-17-2023
By GuruFocusNews GuruFocusNews • 07-07-2022
By GuruFocusNews GuruFocusNews • 06-17-2022
By sperokesalga sperokesalga • 03-20-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.